Pay in 4 interest-free payments of $6.08 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Mechanistic Compatibility Matrix Compatible combinations Different biological lanes: Appetite regulation + peripheral lipolysis Metabolic regulation + tissue repair Weight loss therapy + muscle preservation strategy Potentially redundant combinations Same biological pathway: GLP-1 + GLP-1 mimetic Multiple fat-loss peptides targeting identical signaling Multiple GH secretagogues Redundant stacks increase risk without improving outcomes
Results differ for everyone
doi: 10.1016/j.cmet.2021.12.010 Summary Keywords GIP, GLP-1, obesity, weight loss, tirzepatide, GLP-1R agonists, GIP receptor agonists, Citation Zaffina I, Pelle MC, Armentaro G, Giofr F, Cassano V, Sciacqua A and Arturi F (2023) Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity
Future trials should be structured to assess whether initiating treatment in high-risk, cognitively unimpaired individuals (e.g., those with type 2 diabetes mellitus, obesity, and/or specific genetic risk factors such as APOE4) can delay or prevent cognitive decline onset
Activating the body's natural receptors to produce GLP-1 to significant levels, Calocurb can be used as 1) a stand-alone weight loss tool, 2) to support people coming off GLP-1 injectables to maintain weight lost, and 3) as a complement to people requiring a lower dose of the injectable
